Fluorine-18-radiolabeled pharmaceuticals for imaging with positron emission tomography, excluding [18F]-fluorodeoxyglucose

Drugs of the Future

Volumn 27, Issue 7, 2002, Pages 655-667

  Pauwels, E K J ^a   Van der Klaauw, A A ^a   Corporaal, T ^a   Stokkel, M P M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 16ALPHA FLUOROESTRADIOL F 18; 16BETA,5ALPHA DIHYDROTESTOSTERONE F 18; 17ALPHA ETHYNYL 16BETA FLUORO 11BETA METHOXYESTRADIOL F 18; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (3 FLUOROPROPYL) ACETAMIDE F 18; 2 (2 NITROIMIDAZOL 1H YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; 2 (2 NITROIMIDAZOL 1H YL) N (3,3,3 TRIFLUOROPROPYL)ACETAMIDE F 18; 3' DEOXY 3' FLUOROTHYMIDINE F 18; 4 BORONO 2 FLUORO DEXTRO PHENYLALANINE F 18; 4 FLUOROPROLINE F 18; 7ALPHA FLUORO 17ALPHA METHYL 5ALPHA DIHYDROTESTOSTERONE F 18; 9 [(3 FLUORO 1 HYDROXY 2 PROPOXY)METHYL]GUANINE F 18; ALPHA INTERMEDIN F 18; AMINO ACID; ARGINYLGLYCYLASPARTIC ACID F 18; ETHYLTYROSINE F 18; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROETANIDAZOLE F 18; METIROSINE F 18; NEUROTENSIN[8-13] F 18 ANALOG; NORPROGESTERONE F 18; OCTREOTIDE F 18; PEPTIDE; PHENYLALANINE F 18; PROTEIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE F 18;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG STRUCTURE; DRUG SYNTHESIS; GENE EXPRESSION; GENE THERAPY; HUMAN; ISOTOPE LABELING; NONHUMAN; PEPTIDE SYNTHESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN SYNTHESIS; REVIEW; TUMOR GROWTH;

EID: 0036660195     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.07.683135     Document Type: Review

References (125)

1. 18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 2000, 126: 560-74.
2. Bury, T., Barreto, A., Daenen, F., Barthelemy, N., Ghaye, B., Rigo, P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with nonsmall cell lung cancer. Eur J Nucl Med 1998, 25: 1244-7.
3. Okarvi, S.M. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med 2001, 28: 929-38.
4. 18F]labelled peptides for positron emission tomography. Bioorg Med Chem Lett 2000, 10: 1501-3.
5. 18F]fluorobenzoate. J Labelled Comp Radiopharmaceut 2001, 44: 509-19.
6. 18F-Labeled fluorodeoxyglucose for PET imaging: The working mechanism and its clinical implication. Drugs Fut 2001, 26: 659-68.
7. -11C]-tyrosine for the visualization of tumors and measurement of the protein synthesis rate. J Nucl Med 1997, 38: 191-5.
8. 18F-α-methyl]tyrosine in mice bearing colorectal carcinoma LS-180. Anticancer Drugs 1999, 10: 329-36.
9. Inoue, T., Tomiyoshi, K., Higuichi, T. et al. Biodistribution studies on L-3-[fluorine-18]fluoro-α-methyl tyrosine: A potential tumor-detecting agent. J Nucl Med 1998, 39: 663-7.
10. 18F α-Methyl tyrosine PET studies in patients with brain tumors. J Nucl Med 1999, 40: 399-405.
11. Watanabe, H., Inoue, T., Shinozaki, T. et al. K. PET imaging of musculoskeletal tumours with fluorine-18 α-methyltyrosine: Comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med 2000, 27: 1509-17.
12. 18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 1999, 40: 1367-73.
13. 18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 1999, 40: 205-12.
14. -11C]methionine uptake in brain tumours: Initial results of a comparative study. Eur J Nucl Med 2000, 27: 542-9.
15. 11C-Methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998, 50: 1316-22.
16. Kaschten, B., Stevenaert, A., Sadzot, B. et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998, 39: 778-85.
17. 18F-fluorophenylalanine positron emission tomography. Eur J Radiol 1997, 25: 30-5.
18. Ogawa, T., Miura, S., Murakami, M. et al. K. Quantitative evaluation of neutral amino acid transport in cerebral gliomas using positron emission tomography and fluorine-18 fluorophenylalanine. Eur J Nucl Med 1996, 23: 889-95.
19. 18F]fluoro-L-proline in urologic tumors. J Nucl Med 2001, 42: 752-4.
20. 18)F]fluoro-L-proline. Nucl Med Biol 2001, 28: 287-92.
21. Gahbauer, R., Gupta, N., Blue, T. et al. Boron neutron capture therapy: Principles and potential. Recent Results Cancer Res 1998, 150: 183-209.
22. Imahori, Y., Ueda, S., Ohmori, Y. et al. Fluorine-18-labeled fuoroboronophenylalanine PET in ptients wth gioma. J Nucl Med 1998, 39: 325-33.
23. 18F-DOPA analogue. J Neurooncol 1997, 33: 163-9.
24. Clezardin, P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci 1998, 54: 541-8.
25. Stromblad, S., Cheresh, D.A. Integrins, angiogenesis and vascular cell survival. Chem Biol 1996, 3: 881-5.
26. Haubner, R., Wester, H.J., Burkhart, F. et al. M. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001, 42: 326-36.
27. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001, 61: 1781-5.
28. Pavey, S., Gabrielli, B. α-Melanocyte stimulating hormone potentiates P16/CDKN2A expression in human skin after ultraviolet irradiation. Cancer Res 2002, 62: 875-80.
29. 7]-α-MSH, an α-melanocyte stimulating hormone analogue. Nucl Med Biol 1997, 24: 171-8.
30. 86Y-DTPA-octreotide. Nucl Med Biol 1997, 24: 275-86.
31. Breeman, W.A., de Jong, M., Kwekkeboom, D.J. et al. Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations and future perspectives. Eur Nucl Med 2001, 28: 1421-9.
32. 18F-labeled neurotensin(8-13) analogs. Nucl Med Biol 2002, 29: 61-72.
33. Moody, T.W., Leyton, J., Unsworth, E., John, C., Lang, L., Eckelman, W.C. (Arg15,Arg21) VIP: Evaluation of biological activity and localization to breast cancer tumors. Peptides 1998, 19: 585-92.
34. Chretien, S., Moreau-Gachelin, F., Apiou, F. et al. Putative oncogenic role of the erythropoietin receptor in murine and human erythroleukemia cells. Blood 1994, 83: 1813-21.
35. Aloj, L., Lang, L., Jagoda, E., Neumann, R.D., Eckelman, W.C. Evaluation of human transferrin radiolabeled with N-succinimidyl 4-[fluorine-18](fluoromethyl) benzoate. J Nucl Med 1996, 37: 1408-12.
36. 18F](fluoromethyl) benzoate. Appl Radiat Isot 1997, 48: 169-73.
37. 18F]Fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001, 42: 679-84.
38. 18F]fluoro-17β-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996, 2: 933-9.
39. Behr, T.M., Behe, M., Becker, W. Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med 1999, 43: 268-80.
40. Moresco, R.M., Scheithauer, B.W., Lucignani, G. et al. Oestrogen receptors in meningiomas: A correlative PET and immunohistochemical study. Nucl Med Commun 1997, 18: 606-15.
41. Jonson, S.D., Welch, M.J. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med 1998, 42: 8-17.
42. 18F]fluoro-16α-ethyl-19-norprogesterone) in humans: A clue for future investigations. Nucl Med Biol 1994, 21: 941-52.
43. Bonasera, T.A., O'Neil, J.P., Xu et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med 1996, 37: 1009-15.
44. 18F]Fluoro-17α-methyl-5α-dihydrotestosterone: A ligand for androgen receptor-mediated imaging of prostate cancer. Nucl Med Biol 2001, 28: 85-90.
45. Fyles, A.W., Milosevic, M., Wong, R. et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998, 48: 149-56.
46. Hockel, M., Schlenger, K., Hockel, S., Vaupel, P. Association between tumor hypoxia and malignant progression: The clinical evidence in cancer of the uterine cervix. In: Tomour Hypoxia. Vaupel, P., Kelleher, D.K. (Eds.). Wissenschafte Verlags GmbH: Stuttgart 1999, 65.
47. Nordsmark, M., Overgaard, M., Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996, 41: 31-9.
48. Lewis, J.S., Welch, M.J. PET imaging of hypoxia. Q J Nucl Med 2001, 45: 183-8.
49. Ballinger, J.R. Imaging hypoxia in tumors. Semin Nucl Med 2001, 31: 321-9.
50. Liu, R.S., Chang, C.P., Chao, I. et al. Tumor hypoxia in hepatocellular carcinoma detected by F-18-fluoromisonidazole positron emission tomography. J Nucl Med 2001, 42: 111.
51. 18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol 2000, 27: 693-700.
52. Rasey, J.S., Casciari, J.J., Hofstrand, P.D., Muzi, M., Graham, M.M., Chin, L.K. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res 2000, 153: 84-92.
53. Piert, M., Machulla, H., Becker, G. et al. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur J Nucl Med 1999, 26: 95-109.
54. 18F]fluoromisonidazole (FMISO). Nucl Med Biol 2002, 29: 191-7.
55. 18F]FETNIM: A potential marker for PET. J Nucl Med 2001, 42: 1397-404.
56. 18F]fluoroerythronitroimidazole PET. J Nucl Med 2002, 42: 1643-52.
57. 18F]EF1. J Nucl Med 2000, 41: 327-36.
58. Kachur, A.V., Dolbier, W.R., Evans, S.M. et al. Synthesis of new hypoxia markers EF1 and [F-18]-EF1. Appl Radiat Isot 1999, 51: 643-50.
59. Josse, O., Labar, D., Georges, B., Gregoire, V., Marchand-Brynaert, J. Synthesis of [F-18]-labeled EF3 [2-(2-nitroimidazol1-YI)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia. Bioorg Med Chem 2001, 9: 665-75.
60. Dolbier, W.R., Li, A.R., Koch, C.J., Shiue, C.Y., Kachur, A.V. [F-18]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 2001, 54: 73-80.
61. Tewson, T.J. Synthesis of [F-18]fluoroetanidazole: A potential new tracer for imaging hypoxia. Nucl Med Biol 1997, 24: 755-60.
62. 18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999, 40: 1072-9.
63. Rasey, J.S., Grunbaum, Z., Magee, S. et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987, 111: 292-304.
64. Koh, W.J., Bergman, K.S., Rasey, J.S. et al. Evaluation of oxygenation status during fractionated radiotherapy in human non-small cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995, 33: 391-8.
65. Liu, R.S., Chu, L.S., Yen, S.H. et al. Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole. Eur J Nucl Med 1996, 23: 1384-7.
66. Yeh, S.H., Liu, R.S., Wu, L.C. et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996, 23: 1378-83.
67. 18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996, 36: 417-28.
68. Yang, D.J., Wallace, S., Cherif, A. et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995, 194: 795-800.
69. Koch, C.J., Evans, S.M., Lord, E.M. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: Analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 1995, 72: 869-74.
70. Evans, S.M., Joiner, B., Jenkins, W.T., Laughlin, K.M., Lord, E.M., Koch, C.J. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]. Br J Cancer 1995, 72: 875-82.
71. Evans, S.M., Jenkins, W.T., Joiner, B., Lord, E.M., Koch, C.J. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res 1996, 56: 405-11.
72. Laughlin, K.M., Evans, S.M., Jenkins, W.T. et al. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl)acetamide) in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther 1996, 277: 1049-57.
73. Rochlitz, C.F. Gene therapy of cancer. Swiss Med Wkly 2001, 131: 4-9.
74. Curiel, D.T., Gerritsen, W.R., Krul, M.R. Progress in cancer gene therapy. Cancer Gene Ther 2000, 7: 1197-9.
75. Gambhir, S.S., Barrio, J.R., Herschman, H.R., Phelps, M.E. Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol 1999, 26: 481-90.
76. Herschman, H.R., MacLaren, D.C., Iyer, M. et al. Seeing is believing: Non-invasive, quantitative and repetitive imaging of reporter gene expression in living animals, using positron emission tomography. J Neurosci Res 2000, 59: 699-705.
77. Gambhir, S.S., Barrio, J.R., Phelps, M.E. et al. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci USA 1999, 96: 2333-8.
78. 18F]FHBG: A reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med 2001, 42: 1225-34.
79. 124/125I]FIAU for imaging herpes simplex virus type 1 thymidine kinase gene expression. Eur J Nucl Med 2001, 28: 721-9.
80. Hospers, G.A., Calogero, A., van Waarde, A. et al. Monitoring of herpes simplex virus thymidine kinase enzyme activity using positron emission tomography. Cancer Res 2000, 60: 1488-91.
81. 18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors. Nucl Med Biol 1999, 26: 371-6.
82. Hustinx, R., Shiue, C.Y., Alavi, A. et al. Imaging in vivo herpes simplex virus thymidine kinase gene transfer to tumour-bearing rodents using positron emission tomography and [F-18]FHPG. Eur J Nucl Med 2001, 28: 5-12.
83. Shiue, G.G., Shiue, C.Y., Lee, R.L. et al. A simplified one-pot synthesis of 9-[(3-[F-18]fluoro-1-hydroxy-2-propoxy)methyl]guanine ([F-18]FHPG) and 9-(4-[F-18]fluoro-3-hydroxymethylbutyl)guanine ([F-18]FHBG) for gene therapy. Nucl Med Biol 2001, 28: 875-83.
84. 18F]-FHPG): A potential imaging agent of viral infection and gene therapy using PET. Nucl Med Biol 1996, 23: 787-92.
85. MacLaren, D.C., Toyokuni, T., Cherry, S.R. et al. PET imaging of transgene expression. Biol Psychiat 2000, 48: 337-48.
86. Gambhir, S.S., Barrio, J.R., Wu, L. et al. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med 1998, 39: 2003-11.
87. Gambhir, S.S., Bauer, E., Black et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA 2000, 97: 2785-90.
88. 18F]Fluoropenciclovir: An improved reporter probe for imaging HSV1-Tk reporter gene expression in vivo using PET. J Nucl Med 2001, 42: 96-105.
89. Yaghoubi, S.S., Wu, L., Liang, Q. et al. Direct correlation between positron emission tomographic images of two reporter genes delivered by two distinct adenoviral vectors. Gene Ther 2001, 8: 1072-80.
90. 18F]-FHBG): A new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol 1998, 25: 175-80.
91. Alauddin, M.M., Shahinian, A., Gordon, E.M., Conti, P.S. Evaluation of F-18 9-(4-fluoro-3-hydroxymethylbutyl)guanine ([F18]FHBG) as a PET imaging agent for gene expression in tumour bearing mice. J Nucl Med 1999, 40(Suppl.): 26P.
92. Iyer, M., Bauer, E., Barrio, J.R. et al. Comparison of FPCV, FHBG and FIAU as reporter probes for imaging herpes simplex virus type 1 thymidine kinase reporter gene expression. J Nucl Med 2000, 41 (Suppl.): 80P.
93. Krohn, K.A., Mankoff, D.A., Eary, J.F. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 2001, Suppl: 96S-103S.
94. Shields, A.F., Grierson, J.R., Dohmen, B.M. et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998, 4: 1334-6.
95. 18F]FLT, portrait of a proliferation marker. Eur J Nucl Med 2002, 29: 165-9.
96. Shields, A.F., Dohmen, B.M., Grierson, J.R., Kuntzsch, M., Machulla, H., Bares, R. Imaging with [F-18]FLT and FDG in patients with cancer. J Nucl Med 1999, 40(Suppl.): 61P.
97. 18F]FLT. J Nucl Med 2000, 41 (Suppl.): 74P.
98. 18F]FDG for tumor PET: First results of a comparative study. J Nucl Med 2002, 41(Suppl.): 74P.
99. 18F]FLT-PET in brain tumors. J Nucl Med 2000, 41(Suppl.): 216P.
100. 18F]FLT for breast cancer imaging. J Nucl Med 2001, 42(Suppl.): 29P.
101. Shields, A.F., Dohmen, B.M., Mangner, T.J. et al. Use of [F-18]FLT for imaging gastrointestinal tumors. J Nucl Med 2001, 42(Suppl.): 29P.
102. 18F]fluorouracil pharmacokinetics. J Nucl Med 2000, 41: 1714-24.
103. Saleem, A., Yap, J., Osman, S. et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: In-vivo imaging of drug action. Lancet 2000, 355: 2125-31.
104. 18F]fluorouracil. J Nucl Med 1998, 39: 1370-6.
105. Meikle, S.R., Matthews, J.C., Brock, C.S. et al. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: A feasibility study. Cancer Chemother Pharmacol 1998, 42: 183-93.
106. 18F-Labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 1998, 83: 245-53.
107. Dimitrakopoulou-Strauss, A., Strauss, L.G., Schlag, P. et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998, 39: 1197-202.
108. Coleman, R., DeGrado, T., Wang, S. et al. Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 2000, 3: 147.
109. 18Ffluorocholine. J Nucl Med 2002, 43: 92-6.
110. 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res 2001, 61: 110-7.
111. 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001, 42: 1805-14.
112. 18F-fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002, 43: 187-99.
113. 18F-Fluorocholine: A new oncologic PET tracer. J Nucl Med 2001, 42: 1815-7.
114. 18F]fluoroethyluracil. J Pharm Sci 1996, 85: 339-44.
115. 18F]fluoro-2′-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model. Cancer Res 2001, 61: 3853-7.
116. Zeisel, S.H., Blusztajn, J.K. Choline and human nutrition. Annu Rev Nutr 1994, 14: 269-96.
117. Bem, W.T., Thomas, G.E., Mamone, J.Y. et al. Overexpression of sigma receptors in nonneural human tumors. Cancer Res 1991, 51: 6558-62.
118. Mach, R.H., Smith, C.R., al Nabulsi, I., Whirrett, B.R., Childers, S.R., Wheeler, K.T. Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 1997, 57: 156-61.
119. 18F]fluorobenzamide: A potential ligand for PET imaging of sigma receptors. Nucl Med Biol 1997, 24: 671-6.
120. 18F]fluorobenzamide: A potential ligand for PET imaging of breast cancer. Nucl Med Biol 2000, 27: 763-7.
121. 18F]labeled benzamides: High affinity sigma receptor ligands for PET imaging. Nucl Med Biol 1997, 24: 333-40.
122. Matsuno, K., Nakazawa, M., Okamoto, K., Kawashima, Y., Mita, S. Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur J Pharmacol 1996, 306: 271-9.
123. 18F]fluoroethyl SA4503 as a PET ligand for the sigma receptor. Synapse 2002, 43: 259-67.
124. 18F]1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: A selective σ-1 receptor radioligand for PET. Nucl Med Biol 1997, 24: 127-34.
125. 125I]IUDR. Nucl Med Biol 2001, 28: 451-8.